Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Total Liabilities : ¥4,023 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Total Liabilities?

Tianjin Pharmaceutical Da Ren Tang Group's Total Liabilities for the quarter that ended in Mar. 2024 was ¥4,023 Mil.

Tianjin Pharmaceutical Da Ren Tang Group's quarterly Total Liabilities declined from Sep. 2023 (¥3,764.45 Mil) to Dec. 2023 (¥3,584.86 Mil) but then increased from Dec. 2023 (¥3,584.86 Mil) to Mar. 2024 (¥4,022.90 Mil).

Tianjin Pharmaceutical Da Ren Tang Group's annual Total Liabilities increased from Dec. 2021 (¥2,553.26 Mil) to Dec. 2022 (¥3,605.03 Mil) but then declined from Dec. 2022 (¥3,605.03 Mil) to Dec. 2023 (¥3,584.86 Mil).

Tianjin Pharmaceutical Da Ren Tang Group Total Liabilities Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Total Liabilities Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

2,319.97

2,333.49

2,553.26

3,605.03

3,584.86

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															3,933.82	3,974.36	3,764.45	3,584.86	4,022.90

Tianjin Pharmaceutical Da Ren Tang Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Tianjin Pharmaceutical Da Ren Tang Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3232.922	+	(243.778	+	108.164
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	3,585

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	10230.101	-	6645.237
	=	3,585

Tianjin Pharmaceutical Da Ren Tang Group's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	3671.922	+	(243.338	+	107.635
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	4,023

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	11050.623	-	7027.727
	=	4,023

Tianjin Pharmaceutical Da Ren Tang Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Total Liabilities

Traded in Other Exchanges

T14:Singapore

Address

No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193

Website

http://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines